BioNTech pays $205M for Scholar Rock’s rare pediatric priority review voucher
- Scholar Rock’s SEC filing says a buyer will pay $205M cash at closing for its Rare Pediatric Disease Priority Review Voucher; German outlets identify BioNTech as the buyer.
- Closing is subject to customary conditions, including antitrust clearance.
- BioNTech reportedly plans to use the voucher for an unnamed late-stage oncology candidate.
💡 Points Based on public reports
A voucher cuts a standard FDA review down to roughly six months, so $205M is effectively the price of time on a drug whose peak sales justify it. For BioNTech it is a cheap way to pull forward a launch while it cuts costs elsewhere; for Scholar Rock it is non-dilutive cash. Voucher prices that hold this high suggest supply stays scarce, which matters for any small rare-disease biotech planning around a sale.
📰 Source · Endpoints News ↗ BioNTech pays $205M for Scholar Rock voucher; J&J pulls back in Norway